Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with Tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: Results from the ACTG A5175 PEARLS study

• المؤلفون الرئيسيون: Celum C., Hong T., Cent A., Donnell D., Morrow R., Baeten J., Firnhaber C., Grinsztejn B., Hosseinipour M., Lalloo U., Nyirenda M., Riviere C., Sanchez J., Santos B., Supparatpinyo K., Hakim J., Kumarasamy N., Campbell T.
• التنسيق: دورية
• منشور في: 2017
• الوصول للمادة أونلاين: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85019691645&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/40651

© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. Objective: Tenofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity against herpes simplex virus type 2 (HSV-2) and reduced HSV-2 acquisition as preexposure prophylaxis....